The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients

Journal of Critical Care

Volumn 25, Issue 2, 2010, Pages 287-293

  Crowther, Mark Andrew ^a   Cook, Deborah J ^a   Albert, Martin ^b   Williamson, David ^b   Meade, Maureen ^a   Granton, John ^c   Skrobik, Yoanna ^b   Langevin, Stephan ^d   Mehta, Sangeeta ^c   Hebert, Paul ^e   Guyatt, Gordon H ^a   Geerts, William ^c   Rabbat, Christian ^a   Douketis, James ^a   Zytaruk, Nicole ^a   Sheppard, Joanne ^a   Greinacher, Andreas ^f   Warkentin, Theodore E ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Cohort study; Heparin; Heparin induced thrombocytopenia; Intensive care; Low molecular weight heparin; Thrombosis

Indexed keywords

ARGATROBAN; DALTEPARIN; DANAPAROID; HEPARIN;

ADULT; ANASTOMOSIS LEAKAGE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL DISEASE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; INTERMETHOD COMPARISON; KIDNEY DISEASE; LENGTH OF STAY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORTALITY; NEUROLOGIC DISEASE; PERITONITIS; PROBABILITY; RESPIRATORY TRACT DISEASE; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SEPSIS; SEROLOGY; SEROTONIN RELEASE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS PREVENTION;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CRITICAL ILLNESS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPARIN; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; SEROTONIN; SURGERY DEPARTMENT, HOSPITAL; THROMBOCYTOPENIA; THROMBOSIS;

EID: 77953286757     PISSN: 08839441     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrc.2009.12.006     Document Type: Article

References (27)

1. Crowther M.A., Cook D.J., Meade M.O., Griffith L.E., Guyatt G.H., Arnold D.M., et al. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care 2005, 20(4):348-353.
2. Warkentin T.E., Sheppard J.A., Moore J.C., Moore K.M., Sigouin C.S., Kelton J.G. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?. J Lab Clin Med 2005, 146(6):341-346.
3. Greinacher A., Juhl D., Strobel U., Wessel A., Lubenow N., Selleng K., et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 2007, 5(8):1666-1673.
4. Selleng K., Warkentin T.E., Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med 2007, 35(4):1165-1176.
5. Napolitano L., Warkentin T.E., Al Mahameed A., Nasraway S.A. Heparin-induced thrombocytopenia in the critical care setting:diagnosis and management. Crit Care Med 2006, 34(12):2898-2911.
6. Warkentin T.E., Elavathil L.J., Hayward C.P., Johnston M.A., Russett J.I., Kelton J.G. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997, 127(9):804-812.
7. Chan M., Malynn E., Shaz B., Uhl L. Utility of consecutive repeat HIT ELISA testing for heparin-induced thrombocytopenia. Am J Hematol 2008, 83(3):212-217.
8. Warkentin T.E., Greinacher A., Koster A., Lincoff A.M. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008, 133(6 Suppl):340S-380S.
9. Brand P.A., Egberts J.H., Scholz J., Weiler N., Bein B. Argatroban therapy in patients with hepatic and renal impairment. Eur J Anaesthesiol 2008, 25(4):344-346.
10. Williamson D.R., Boulanger I., Tardif M., Albert M., Gregoire G. Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy 2004, 24(3):409-414.
11. Lobo B., Finch C., Howard A., Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008 Jan, 99(1):208-214.
12. Greinacher A., Warkentin T.E. The direct thrombin inhibitor hirudin. Thromb Haemost 2008, 99(5):819-829.
13. Lo G.K., JUHL D., Warkentin T.E., Sigouin C.S., Eichler P., Greinacher A. Evaluation of pretest clinical score (4Ts) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006, 4(4):759-765.
14. Cook D.J., Crowther M.A., Meade M., Rabbat C., Schiff D., Geerts W., et al. Deep vein thrombosis in medical-surgical ICU patients: prevalence, incidence and risk factors. Crit Care Med 2005, 31(1):48-55.
15. Cook D.J., Rocker G., Meade M., Guyatt G., Geerts W., Anderson D., et al. Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study. J Crict Care 2005, 20(4):364-372.
16. Cook D., Douketis J., Meade M., Guyatt G., Zytaruk N., Granton J., et al. Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. Crit Care 2008, 12(2):R32.
17. Sheridan D., Carter C., Kelton J.G. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986, 67(1):27-30.
18. Kelton J.G., Sheridan D., Santos A., Smith J., Steeves K., Smith C., et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988, 72(3):925-930.
19. Warkentin T.E., Hayward C.P., Smith C.A., Kelly P.M., Kelton J.G. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992, 120:371-379.
20. Warkentin T.E., Sheppard J.I. Testing for heparin-induced thrombocytopenia (HIT) antibodies. Transfus Med Rev 2006, [in press].
21. Warkentin T.E., Levine M.N., Hirsh J., Horsewood P., Roberts R.S., Gent M., et al. Heparin-induced thrombocytopenia in patients treated with low- molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330-1335.
22. Horsewood P., Warkentin T.E., Hayward C.P., Kelton J.G. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol 1996, 95(1):161-167.
23. Visentin G.P., Moghaddam M., Beery S.E., McFarland J.G., Aster R.H. Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med 2001, 138(1):22-31.
24. Gettings E.M., Brush K.A., Van Cott E.M., Hurford W.E. Outcome of postoperative critically ill patients with heparin-induced thrombocytopenia: an observational retrospective case-control study. Crit Care 2006, 10(6):R161.
25. Verma A.K., Levine M., Shalansky S.J., Carter C.J., Kelton J.G. Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 2003, 23:745-753.
26. Lo G.K., Sigouin C.S., Warkentin T.E. What is the potential for overdiagnosis of heparin-induced thrombocytopenia?. Am J Hematol 2007, 82(12):1037-1043.
27. Lee D.H., Warkentin T.E. Frequency of heparin-induced thrombocytopenia. Heparin-induced thrombocytopenia 2007, 67-116. Informa Healthcare USA, Inc, New York. 4th ed. T.E. Warkentin, A. Greinacher (Eds.).